Summary
Abbott Laboratories (ABT) filed an 8-K on April 20, 2016, to report its first-quarter 2016 financial results. The filing includes a press release detailing the company's performance and financial condition. A key aspect of the report is Abbott's use of non-GAAP financial measures, which management believes provide a clearer view of ongoing business performance by excluding unusual or unpredictable items. Investors should note that these non-GAAP measures adjust for factors such as foreign exchange impacts (specifically mentioning Venezuela), cost reduction initiatives, transaction costs, and tax-related adjustments. While Abbott's management finds these measures useful for internal assessment and for investor understanding, the company advises investors to consider them alongside, and not as a substitute for, their GAAP-reported results.
Key Highlights
- 1Abbott Laboratories reported its Q1 2016 financial results via an 8-K filing.
- 2The report includes a press release detailing operational results and financial condition.
- 3Abbott utilizes non-GAAP financial measures to present performance.
- 4Non-GAAP measures are adjusted for items like foreign exchange losses (Venezuela), cost reductions, transaction costs, and tax adjustments.
- 5The company believes these non-GAAP measures offer better insight into ongoing business performance.
- 6Management uses these non-GAAP measures for internal performance monitoring.
- 7Investors are cautioned to consider non-GAAP measures in conjunction with GAAP results.